{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:57:21Z","timestamp":1649170641931},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/2191-1991-3-13","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T03:35:24Z","timestamp":1367897724000},"source":"Crossref","is-referenced-by-count":4,"title":["Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain"],"prefix":"10.1186","volume":"3","author":[{"given":"Rainel","family":"Sanchez-de la Rosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliazar","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"key":"54_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4137\/JCNSD.S8755","volume":"4","author":"O Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez O: Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis. J Cent Nerv Syst Dis 2012, 4: 117\u2013133.","journal-title":"J Cent Nerv Syst Dis"},{"key":"54_CR2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000, 343: 938\u2013952. 10.1056\/NEJM200009283431307","journal-title":"N Engl J Med"},{"key":"54_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/1352458511421917","volume":"18","author":"O Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez O, Fernandez V, Guerrero M, Leon A, Lopez-Madrona JC, Alonso A, Bustamante R, Tamayo JA, Romero F, Bravo M, Luque G, Garcia L, Sanchis G, San Roman C, Romero M, Papais-Alvarenga M, de Ramon E: Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. Mult Scler 2012, 18: 372\u2013376. 10.1177\/1352458511421917","journal-title":"Mult Scler"},{"key":"54_CR4","volume-title":"Mult.Scler","author":"S Otero-Romero","year":"2012","unstructured":"Otero-Romero S, Roura P, Sola J, Altimiras J, Sastre-Garriga J, Nos C, Vaque J, Montalban X, Bufill E: Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult.Scler 2012."},{"key":"54_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.nrl.2010.03.006","volume":"25","author":"A Garcia Merino","year":"2010","unstructured":"Garcia Merino A, Fernandez O, Montalban X, de Andres C, Arbizu T: Spanish neurology society consensus document on the use of drugs in multiple sclerosis: escalating therapy. Neurologia 2010, 25: 378\u2013390. 10.1016\/j.nrl.2010.03.006","journal-title":"Neurologia"},{"key":"54_CR6","doi-asserted-by":"publisher","first-page":"A548","DOI":"10.1016\/j.jval.2012.08.1938","volume":"15","author":"AJ Garc\u00eda-Ruiz","year":"2012","unstructured":"Garc\u00eda-Ruiz AJ, Izquierdo Ayuso G, GArc\u00eda-Agua Soler N: Budgetary impact of the treatment of relapsing-remitting multiple sclerosis in Spain. Value Health 2012, 15: A548.","journal-title":"Value Health"},{"key":"54_CR7","unstructured":"Copaxone\u00ae Summary of Products Characteristics: AGENCIA ESPA\u00d1OLA DEL MEDICAMENTO Y PRODUCTOS SANITARIOS 2009. http:\/\/www.aemps.gob.es\/cima\/especialidad.do?metodo=verFichaWordPdf&codigo=64205&formato=pdf&formulario=FICHAS"},{"key":"54_CR8","volume-title":"EUROPEAM MEDICINE AGENCY","author":"Gilenya\u00ae Summary of Products Characteristics","year":"2012","unstructured":"Gilenya\u00ae Summary of Products Characteristics: EUROPEAM MEDICINE AGENCY. 2012. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002202\/human_med_001433.jsp&mid=WC0b01ac058001d124"},{"key":"54_CR9","unstructured":"BOE No. 103 Sec I Pag 32653 30 abril 2012: Ley organica 2\/2012 de estabilidad presupuestaria y sostenibilidad financiera. http:\/\/www.boe.es\/boe\/dias\/2012\/04\/30\/pdfs\/BOE-A-2012\u20135730.pdf"},{"key":"54_CR10","unstructured":"Proyecto Presupuestos Generales del Estado 2013. 2013. http:\/\/www.sepg.pap.minhap.gob.es\/sitios\/sepg\/es-ES\/Presupuestos\/ProyectoPGE\/Paginas\/ProyectoPGE2013.aspx"},{"key":"54_CR11","unstructured":"Base de conocimiento de costes y precios del sector sanitario. 2006. http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"54_CR12","volume-title":"Cat\u00e1logo de Medicamentos","author":"Consejo General de Colegios de Farmac\u00e9uticos","year":"2012","unstructured":"Consejo General de Colegios de Farmac\u00e9uticos: Cat\u00e1logo de Medicamentos. 2012. http:\/\/www.portalfarma.com\/inicio\/colecconconsejo\/versionclasica\/catalogomedicam\/Paginas\/catalogodemedicamentos2012.aspx"},{"key":"54_CR13","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. 2010. http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010\u20138228.pdf"},{"key":"54_CR14","first-page":"203","volume":"4","author":"M Chambers","year":"2002","unstructured":"Chambers M, Hutton J, Nuitjen M: Budget impact analysis for health technology appraisal: development and application within the NICE appraisal process. Journal of Clinical Excellence 2002, 4: 203\u2013206.","journal-title":"Journal of Clinical Excellence"},{"key":"54_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00019053-200119060-00001","volume":"19","author":"P Trueman","year":"2001","unstructured":"Trueman P, Drummond M, Hutton J: Developing guidance for budget impact analysis. PharmacoEconomics 2001, 19: 609\u2013621. 10.2165\/00019053-200119060-00001","journal-title":"PharmacoEconomics"},{"issue":"Suppl 2","key":"54_CR16","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s10198-006-0381-y","volume":"7","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, Izquierdo G, Sanchez-Solino O, Perez-Miranda J, Casado MA: Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006,7(Suppl 2):S65-S74.","journal-title":"Eur J Health Econ"},{"key":"54_CR17","first-page":"129","volume":"53","author":"R Sanchez-De la Rosa","year":"2011","unstructured":"Sanchez-De la Rosa R, Sabater E, Casado MA: Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Rev Neurol 2011, 53: 129\u2013138.","journal-title":"Rev Neurol"},{"key":"54_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12325-009-0028-3","volume":"26","author":"J Castelli-Haley","year":"2009","unstructured":"Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP: Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 2009, 26: 552\u2013562. 10.1007\/s12325-009-0028-3","journal-title":"Adv Ther"},{"key":"54_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.18553\/jmcp.2007.13.1.44","volume":"13","author":"JD Prescott","year":"2007","unstructured":"Prescott JD, Factor S, Pill M, Levi GW: Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007, 13: 44\u201352.","journal-title":"J Manag Care Pharm"},{"key":"54_CR20","doi-asserted-by":"publisher","first-page":"A 233","DOI":"10.1016\/j.jval.2011.01.006","volume":"14","author":"F Pan","year":"2011","unstructured":"Pan F, Goh J, Wang C, Meinhardt M: Cost-minimization analysis of IFNB-1b and fingolimod among multiple sclerosis patients in Germany. Value Health 2011, 14: A 233-A 510.","journal-title":"Value Health"},{"key":"54_CR21","doi-asserted-by":"publisher","first-page":"A 317","DOI":"10.1016\/j.jval.2011.08.467","volume":"14","author":"SM Szabo","year":"2011","unstructured":"Szabo SM, Dembek C, Moore P, White LA, Wijaya H, Levy AR: Estimating net health benefits of intramuscular interferon beta-1a and fingolimod in treating patients with relapsing-remitting multiple sclerosis. Value Health 2011, 14: A 317.","journal-title":"Value Health"},{"key":"54_CR22","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s00415-008-0910-y","volume":"255","author":"LJ Julian","year":"2008","unstructured":"Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC: Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol 2008, 255: 1354\u20131360. 10.1007\/s00415-008-0910-y","journal-title":"J Neurol"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2191-1991-3-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T05:49:42Z","timestamp":1644990582000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/2191-1991-3-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1186\/2191-1991-3-13","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,7]]},"article-number":"13"}}